Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children.
In recent years, bisphosphonates, primarily intravenous (iv) pamidronate, have become very widely used in children with severe osteogenesis imperfecta (OI). This has occurred without the well-controlled clinical trials usually required before a medication becomes 'standard care'. Without placebo-controlled trials it is difficult to define precisely the risks and the benefits, but in children with very severe OI and numerous fractures the risk/benefit ratio is so clearly favorable that widespread use of pamidronate in this situation appears appropriate.
Henderson
Richard
R
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology; D002547:Cerebral Palsy / Q000150:complications / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000008:administration & dosage*; D019988:Children with Disabilities; D004305:Dose-Response Relationship, Drug; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D051346:Mobility Limitation; D010013:Osteogenesis Imperfecta / Q000188:drug therapy; D000077268:Pamidronate
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate